Eisai said recently it had submitted a marketing application to the European health regulator for review of its Alzheimer’s drug lecanemab, which was recently granted accelerated approval in the United States (US).
The drug, developed in partnership with Biogen, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of those in the early stages of the mind-wasting disease.
Eisai also reiterated its plans to apply for marketing authorisation of the drug in Japan by the end of the business year on 31st March.
Edits by EP News Bureau
Your blog is very informative. thanks for Sharing this blog.